<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390387</url>
  </required_header>
  <id_info>
    <org_study_id>ALL-MB 2015</org_study_id>
    <nct_id>NCT03390387</nct_id>
  </id_info>
  <brief_title>Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)</brief_title>
  <acronym>ALL-MB 2015</acronym>
  <official_title>Moscow-Berlin 2015 Multicenter Randomized Study for Treatment of Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      QUESTIONS AND OBJECTIVES OF ALL-MB 2015 STUDY

        1. Will the new risk group stratification (especially of T-ALL) to improve overall and
           event-free survival?

        2. Will the new protocol is effective and feasible in patients older than 15 years, and
           especially in young adults?

        3. Whether the intermittent dexamethasone administration in induction will result in a
           decrease in toxicity and mortality without loss of efficacy?

        4. Whether the methylprednisolone administration as basic glucocorticoids during induction,
           consolidation and maintenance therapy will lead to decrease of severe infections and
           early mortality rate, improve survival and therapy compliance in adolescents and young
           adults with B-precursor ALL?

        5. Whether the administration of Bortezomib in patients with B-precursor ALL with initial
           WBC≥100,000/µl will improve treatment outcome?

        6. Whether the administration of Idarubicin instead Daunorubicin in low-risk T-ALL patients
           and two-phase induction in intermediate-risk T-ALL patients will reduce relapse rate and
           improve survival?
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>3 years, 5 years and 10 years after study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years, 5 years and 10 years after study start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>3 years, 5 years and 10 years after study start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early death rate</measure>
    <time_frame>3 years, 5 years and 10 years after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission death rate</measure>
    <time_frame>3 years, 5 years and 10 years after study start</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Dexa intermittent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy with intermittent Dexamethasone administration (1-15 days - 6 mg/m2, 15-22 day - pause, 22-29 days - 6 mg/m2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexa constant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy with continuous Dexamethasone administration (6 mg/m2 1-29 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapy with Dexamethasone (6 mg/m2) as basic glucocorticoid preparation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapy with Methylprednisolone (60 mg/m2) as basic glucocorticoid preparation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction and consolidation therapy with Idarubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DNR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction and consolidation therapy with Daunorubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol Ib+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two-phase induction therapy (additional second phase of induction - protocol Ib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol Ib-</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard induction therapy (without second phase)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib-</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consolidation therapy without Bortezomib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consolidation therapy with Bortezomib 1.3 mg/m2 N12 (N4 in each reinduction)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone continuous</intervention_name>
    <description>6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.</description>
    <arm_group_label>Dexa constant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone intermittent</intervention_name>
    <description>6 mg/m2, per os, in two divided doses per day q12 hours. Days: 1-14 (dose in the first few days is depending on the total tumor mass) and 22-28; days 15-21 - pause. From day 29 the dose of dexamethasone is reducing: days 29-30 - 3 mg/m2, days 31-32 - 1.5 mg/m2, then dexamethasone is discontinued completely.</description>
    <arm_group_label>Dexa intermittent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Induction: 6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.
Consolidation: 6 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).
Maintenance therapy: 6 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94.</description>
    <arm_group_label>Dexa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Induction: 60 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 30 mg/m2, days 32-34 - 15 mg/m2, days 35-36 - 8 mg/m2; then methylprednisolone is discontinued completely.
Consolidation: 60 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).
Maintenance therapy: 60 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94.</description>
    <arm_group_label>Medrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Induction: 45 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 30 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).</description>
    <arm_group_label>DNR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Induction: 10 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 8 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).</description>
    <arm_group_label>IDA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>1.3 mg/м2, intravenously, bolus injection. Days 85, 89, 92, 96 (consolidation S1); 141, 145, 148, 152 (consolidation S2) and 197, 201, 204, 208 (consolidation S3).</description>
    <arm_group_label>Bortezomib+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Second phase of induction</intervention_name>
    <description>Cyclophosphamide (1,000 mg/m2, intravenously, for 1 hour ‒ days 43 and 71); Cytarabine (75 mg/m2/day, intravenously, bolus injection. Four blocks of 4 days each, days 46-48, 52-55, 59-62, and 66-69); 6-mercaptopurine (60 mg/m2/day, per os, days 43-71); Triple intrathecal therapy (days 52 and 66)</description>
    <arm_group_label>Protocol Ib+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard induction therapy</intervention_name>
    <description>Dexamethasone (6 mg/m2, p/o; 1-29 days); Daunorubicin (45 mg/m2, i.v.; day 8 and 22); Vincristine (1.5 mg/m2, i.v.; days 8, 15, 22, 29 and 36); Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)</description>
    <arm_group_label>Protocol Ib-</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard consolidation therapy</intervention_name>
    <description>Consolidation consists of 3 phases: S1, S2 and S3. Each phase is a 6-week therapy with 6-mercaptopurine (50 mg/m2 per day, daily, orally), methotrexate (30 мг/м2, i.m., weekly) and L-asparaginase (10 000 U/m2, i.m., weekly), followed by 2 weeks of re-induction with Vincristine (1.5 mg/m2, i.v., days 1 and 8 of reinduction) plus Dexamethasone (6 mg/m2, p/o, daily, for 10 days followed by quick discontinuation during 3 days). Daunorubicin (30 mg/м2, i.v., N2 during S1, N2 during S2 and N1 during S3). Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone) N12 (4 injections per each phase)</description>
    <arm_group_label>Bortezomib-</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at diagnosis at 1 to 50 years.

          -  The start of induction therapy within a time interval of study recruitment phase.

          -  The diagnosis of ALL is to be proved by the morphological, cytochemical, and
             immunological analysis of tumor cells in bone marrow (see &quot;Diagnostics&quot;). Patients
             with B-cell (Burkitt) ALL are excluded.

          -  Informed consent of the patient parents (guardians) to be treated in one of the
             clinics included in this multicenter study.

        Exclusion Criteria:

          -  ALL is a second malignancies;

          -  The disease is a relapse of previously misdiagnosed and, therefore, inadequately
             treated ALL;

          -  There is severe concomitant disease, which significantly impedes chemotherapy protocol
             (such as multiple malformations, heart diseases, metabolic disorders, etc.);

          -  There is a lack of important data needed for the exact adherence to the cytostatic
             therapy according to a specific chemotherapy protocol (differential diagnosis of
             ALL-AML (acute myeloid leukemia) is not possible, stratification according to
             therapeutic group is not possible);

          -  The patient was treated before for a long time with cytotoxic drugs;

          -  There were treatment deviations not covered by the protocol and/or not due to side
             effects of treatment and/or complications of the disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander I. Karachunskiy, Professor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of Pediatric Hematology, Oncology and Immunology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander I. Karachunskiy, Professor, MD</last_name>
    <phone>+7-926-218-84-09</phone>
    <email>info@mbstudy.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia V. Roumiantseva, MD. PhD</last_name>
    <phone>+7-903-730-39-78</phone>
    <email>j.roumiantseva@mbstudy.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>prof. R.O.Eolyan Hematology Center</name>
      <address>
        <city>Ereván</city>
        <country>Armenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republican Research and Practical Center of Radiation Medicine and Human Ecology</name>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republic Research and Practical Center of Pediatric Oncology, Hematology and Immunology</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mogilev Regional Children's Hospital</name>
      <address>
        <city>Mogilev</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Oncology and Hematology Center, Ministry of Health of the Kyrgyz Republic</name>
      <address>
        <city>Bishkek</city>
        <country>Kyrgyzstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Regional Clinical Children's Hospital</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Children's Hospital</name>
      <address>
        <city>Astrakhan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Altay Regional Clinical Children's Hospital</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amur Regional Clinical Children's Hospital</name>
      <address>
        <city>Blagoveshchensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bryansk Regional Children's Hospital</name>
      <address>
        <city>Bryansk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical Children's Hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Transbaikal Regional Oncology Dispensary</name>
      <address>
        <city>Chita</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irkutsk Regional Children Clinical Hospital</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ivanovo Regional Clinical Hospital</name>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republic Clinical Children's Hospital</name>
      <address>
        <city>Izhevsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Children's Hospital</name>
      <address>
        <city>Khabarovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kirov Research Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Children's Hospital</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Territorial Clinical Children's Hospital</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurgan Regional Clinical Children's Hospital</name>
      <address>
        <city>Kurgan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Children's Hospital</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Children's Hospital</name>
      <address>
        <city>Lipetsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republic Children's Clinical Hospital</name>
      <address>
        <city>Makhachkala</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morozov Children's Municipal Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Institute of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Russian Children's Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Murmansk Clinical Children's Hospital</name>
      <address>
        <city>Murmansk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republic Clinical Children's Hospital</name>
      <address>
        <city>Nal'chik</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nizhnevartovsk Regional Clinical Children's Hospital</name>
      <address>
        <city>Nizhnevartovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Children's Hospital</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novokuznetsk Municipal Clinical Children's Hospital N4</name>
      <address>
        <city>Novokuznetsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novosibirsk Central District Clinical Hospital</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orenburg Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Children's Hospital</name>
      <address>
        <city>Orël</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Perm Territorial Clinical Children's Hospital</name>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Children's Hospital</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rostov Research Institute of Oncology</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>N. Dmitrieva Ryazan Regional Clinical Children's Hospital</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Center</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Municipal Hospital N1</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Clinical Hospital N31</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>N.N.Petrov National Medical Research Oncology Center</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>R. Gorbacheva Research Institute of Pediatric Hematology and Transfusiology; Pavlov First Saint-Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Clinical Children's Hospital N1</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Children's Clinical Hospital</name>
      <address>
        <city>Stavropol</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Surgut Regional Clinical Hospital</name>
      <address>
        <city>Surgut</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republic Clinical Children's Hospital</name>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tomsk Regional Clinical Hospital</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tula Regional Clinical Children's Hospital</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republic Clinical Children's Hospital</name>
      <address>
        <city>Ulan-Ude</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ulyanovsk Regional Children's Clinical Hospital</name>
      <address>
        <city>Ulyanovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Children's Clinical Hospital N1, Territorial Children's Hematological Center</name>
      <address>
        <city>Vladivostok</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vologda Regional Clinical Children's Hospital</name>
      <address>
        <city>Vologda</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Voronezh Regional Clinical Children's Hospital N1</name>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republic Hospital N1 - National Medicine Centre</name>
      <address>
        <city>Yakutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Children's Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Children's Hospital N1; Children Oncology and hematology Center</name>
      <address>
        <city>Yekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Tashkent</city>
        <country>Uzbekistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Armenia</country>
    <country>Belarus</country>
    <country>Kyrgyzstan</country>
    <country>Russian Federation</country>
    <country>Uzbekistan</country>
  </location_countries>
  <link>
    <url>http://www.mbstudy.net</url>
    <description>Study web-site</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</investigator_affiliation>
    <investigator_full_name>Karachunskiy Alexander</investigator_full_name>
    <investigator_title>Deputy director - Director of Institute of Oncology, Radiology and Nuclear Medicine of Federal Research Institute of Pediatric hematology, Oncology and Immunology</investigator_title>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia, children, adolescents, treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

